 |
Samsung Biologics. (Photo = Samsung Biologics) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics said in a public announcement on the 12th that it has signed a KRW 92.7 billion consignment production contract with global pharmaceutical company MSD Switzerland. This is equivalent to 3.09% of sales as of 2022.
The contract period can be changed according to the agreement between the two companies until December 31, 2032.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
